ReviewClinical & developmental immunology2012
Lung cancer: a classic example of tumor escape and progression while providing opportunities for immunological intervention.
Review in Clinical & developmental immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 48 citations in OpenAlex.
- Article
- Solid histological component of adenocarcinoma might play an important role in PD-L1 expression of lung adenocarcinoma.Thoracic cancer · 2022Article
- PD-L1 Expression in Non-Small-Cell Lung Cancer Including Various Adenocarcinoma Subtypes.Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia · 2019Article
- The Role of Immune Escape and Immune Cell Infiltration in Breast Cancer.Breast care (Basel, Switzerland) · 2018Review
- Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors.Cancers · 2018Review
- Antigen presentation of the Oct4 and Sox2 peptides by CD154-activated B lymphocytes enhances the killing effect of cytotoxic T lymphocytes on tumor stem-like cells derived from cisplatin-resistant lung cancer cells.Journal of Cancer · 2018Article
- Fine and Predictable Tuning of TALEN Gene Editing Targeting for Improved T Cell Adoptive Immunotherapy.Molecular therapy. Nucleic acids · 2017Article
- PD-L1 expression as poor prognostic factor in patients with non-squamous non-small cell lung cancer.Oncotarget · 2017Article
- Characterization of genetic aberrations in a single case of metastatic thymic adenocarcinoma.BMC cancer · 2017Article
- Mechanism of immune evasion in breast cancer.OncoTargets and therapy · 2017Review
- PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis.Oncotarget · 2016Article
- Imaging Biomarkers in Immunotherapy.Biomarkers in cancer · 2016Review
- Predictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysis.Translational lung cancer research · 2015Review
- Changes in tumor-antigen expression profile as human small-cell lung cancers progress.Cancer biology & medicine · 2015Article
- Biomarkers in early-stage non-small-cell lung cancer: current concepts and future directions.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2014Review
- Immunologic and clinical effects of targeting PD-1 in lung cancer.Clinical pharmacology and therapeutics · 2014Review
- Small cell lung cancer cells express the late stage gBK tumor antigen: a possible immunotarget for the terminal disease.American journal of translational research · 2014Article
- New modalities of cancer treatment for NSCLC: focus on immunotherapy.Cancer management and research · 2014Review
- [Progress in immunotherapy for non-small cell lung cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2014Review
- The anti-lung cancer activities of steroidal saponins of P. polyphylla Smith var. chinensis (Franch.) Hara through enhanced immunostimulation in experimental Lewis tumor-bearing C57BL/6 mice and induction of apoptosis in the A549 cell line.Molecules (Basel, Switzerland) · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancers remain one of the most common and deadly cancers in the world today (12.5% of newly diagnosed cancers) despite current advances in chemo- and radiation therapies. Often, by the time these tumors are diagnosed, they have already metastasized. These tumors demonstrate the classic hallmarks of cancer in that they have advanced defensive strategies allowing them to escape various standard oncological treatments. Immunotherapy is making inroads towards effectively treating other fatal cancers, such as melanoma, glioblastoma multiforme, and castrate-resistant prostate cancers. This paper will cover the escape mechanisms of bronchogenic lung cancer that must be overcome before they can be successfully treated. We also review the history of immunotherapy directed towards lung cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.